Atherosclerosis
Volume 188, Issue 2 , Pages 260-264 , October 2006

Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells

  • Libin Shi

      Affiliations

    • Division of Cardiology, Department of Internal Medicine, Peking University First Hospital, Xishiqudaji #8, West district, Beijing 100034, China
    • ,
  • Wenghui Ding

      Affiliations

    • Division of Cardiology, Department of Internal Medicine, Peking University First Hospital, Xishiqudaji #8, West district, Beijing 100034, China
    • Corresponding Author InformationCorresponding author. Tel.: +86 10 66551122 2761.
    • ,
  • Dayuan Li

      Affiliations

    • Division of Cardiovascular Medicine, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA
    • ,
  • Zhijian Wang

      Affiliations

    • Division of Cardiology, Department of Internal Medicine, Peking University First Hospital, Xishiqudaji #8, West district, Beijing 100034, China
    • ,
  • Hongfeng Jiang

      Affiliations

    • Department of physiology, Peking University, Beijing 100083, China
    • ,
  • Junhua Zhang

      Affiliations

    • Division of Cardiology, Department of Internal Medicine, Peking University First Hospital, Xishiqudaji #8, West district, Beijing 100034, China
    • ,
  • Chaoshu Tang

      Affiliations

    • Department of physiology, Peking University, Beijing 100083, China

Received 25 May 2005 ,Revised 16 October 2005 ,Accepted 27 October 2005.

References 

  1. Ames RS, Sarau HM, Chambers JK, et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature. 1999;401:282–286
  2. Matsushita M, Shichiri M, Imai T, et al. Co-expression of urotensin II and its receptor (GPR14) in human cardiovascular and renal tissues. J Hypertens. 2001;19:2185–2190
  3. Zhu YZ, Wang ZJ, Zhu YC, et al. Urotensin II causes fatal circulatory collapse in anaesthesized cynomolgus monkeys in vivo: a ‘vasoconstrictor’ with a unique hemodynamic profile. Am J Physiol Heart Circ Physiol. 2004;286:H830–H836
  4. Tzanidis A, Hannan RD, Thomas WG, et al. Henry Krum direct actions of urotensin II on the heart. Implications for cardiac fibrosis and hypertrophy. Circ Res. 2003;93:246
  5. Wang H, Mehta JL, Chen K, Zhang X, Li D. Human urotensin II modulates collagen synthesis and the expression of MMP-1 in human endothelial cells. J Cardiovasc Pharmacol. 2004;44:577–581
  6. Stirrat A, Gallagher M, Douglas SA, et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol. 2001;280:H925–H928
  7. Chen Y, Zhao M, Liu X, Yao W, Yang J, Zhang Z, et al. Urotensin II receptor in the rat airway smooth muscle and its effect on the rat airway smooth muscle cells proliferation. Chin Med Sci J. 2001;16:231–235
  8. Li DY, Chen HJ, Staples ED, et al. Oxidized low-density lipoprotein receptor LOX-1 and apoptosis in human atherosclerotic lesions. J Cardiovasc Pharmacol Ther. 2002;7:147–153
  9. Chen J, Mehta JL, Haider N, et al. Role of caspases in Ox-LDL-induced apoptotic cascade in human coronary artery endothelial cells. Circ Res. 2004;94:370–376
  10. Chen H, Li D, Sawamura T, Inoue K, Mehta JL. Upregulation of LOX-1 expression in aorta of hypercholesterolemic rabbits: modulation by losartan. Biochem Biophys Res Commun. 2000;276:1100–1104
  11. Khan A, Moe GW, Nili N, et al. The cardiac atria are chambers of active remodeling and dynamic collagen turnover during evolving heart failure. J Am Coll Cardiol. 2004;43:68–76
  12. Swynghedauw B. Molecular mechanisms of myocardial remodeling. Physiol Rev. 1999;79:215–262
  13. Weber KT, Sun Y, Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension. 1994;23:869–877
  14. Patella V, Marino I, Arbustini E, et al. Stem cell factor in mast cells and increased mast cell density in idiopathic and ischemic cardiomyopathy. Circulation. 1998;97:971–978
  15. Engels W, Reiters PH, Daemen MJ, Smits JF, van der Vusse GJ. Transmural changes in mast cell density in rat heart after infarct induction in vivo. J Pathol. 1995;177:423–429
  16. Hara M, Ono K, Hwang MW, et al. Evidence for a role of mast cells in the evolution to congestive heart failure. J Exp Med. 2002;195:375–381
  17. Watanabe T, Pakala R, Katagiri T, et al. Synergistic effect of urotensin II with serotonin on vascular smooth muscle cell proliferation. J Hypertens. 2001;19:2191–2196
  18. Watanabe T, Pakala R, Katagiri T, Benedict CR. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation. 2001;104:16–18
  19. Douglas SA, Tayara L, Ohlstein EH, Halawa N, Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet. 2002;359:1990–1997
  20. Nothacker HP, Wang Z, McNeill AM, et al. Identification of the natural ligand of an orphan G-protein-coupled receptor involved in the regulation of vasoconstriction. Nat Cell Biol. 1999;1:383–385
  21. Tamura K, Okazaki M, Tamura M, et al. II-induced activation of extracellular signal-regulated kinase in cultured vascular smooth muscle cells: involvement of cell adhesion-mediated integrin signaling. Life Sci. 2003;72:1049–1060

PII: S0021-9150(05)00720-3

doi: 10.1016/j.atherosclerosis.2005.10.044

Atherosclerosis
Volume 188, Issue 2 , Pages 260-264 , October 2006

Article Tools

* Image Usage & Resolution